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that approximately one in ten had had to change their employment status in order to 
look after the patient, usually a reduction in the number of hours worked. Half of the 
caregivers who had reduced their work hours reported a subsequent loss in income 
(ranging from a575 per month in France to a170 in the UK). 113 caregivers (13%) 
indicated that they receive medication to treat a condition brought on or exacerbated 
by their caregiver role, most frequently anxiety, depression and/or insomnia. Care-
givers also reported signiﬁcant impact on their social lives with 51% recording 
reduction in time available for themselves, 48% indicating a decrease in social activi-
ties and a quarter mentioning reduced ﬁtness. CONCLUSIONS: Caregiving is asso-
ciated with reduced employment and a negative ﬁnancial impact. It may result in 
less free time, social activity, poorer health due to reduced ﬁtness and increased 
medication. The emotional burden of seeing a loved-one suffer is high; however, the 
ﬁnancial and physical health implications of being a caregiver should not be 
underestimated.
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DAILY AVERAGE CONSUMPTION AND AVERAGE DAILY COSTS OF 
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OBJECTIVES: Health plans calculate daily average consumption (DACON) to 
compare utilization and costs-per-day of therapy across medications with similar 
therapeutic indications. The purpose of this study is to examine DACON for dulox-
etine across its US-approved indications in major depressive disorder (MDD), general-
ized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), and 
ﬁbromyalgia (FM) and to compare these results with those for venlafaxine-XR and 
pregabalin. METHODS: A retrospective analysis of commercially insured patients 
from large US health plans receiving q1 prescription for duloxetine, venlafaxine-XR, 
or pregabalin during 2006 and 2007 was conducted. MDD and GAD patient sub-
groups were constructed for duloxetine and venlafaxine-XR and DPNP and FM for 
duloxetine and pregabalin. Subgroup assignments were based on ICD-9 diagnosis 
codes recorded during the 12 months prior to the ﬁrst prescription for each index 
medication during the study interval. DACON was calculated by dividing total units 
dispensed by total days of supply. Units-per-day were converted to costs-per-day using 
June 2009 new wholesale prices.1 RESULTS: A total of 79,119 duloxetine, 97,369 
venlafaxine-XR, and 50,512 pregabalin patients were included in the 2007 analysis. 
DACON for duloxetine was 1.31 capsules per day, ranging between 1.27 for DPNP, 
1.33 for GAD, 1.39 for FM, and 1.52 for MDD. Average daily cost for duloxetine 
was $5.20 varying from $5.07 (DPNP) to $6.06 (MDD). DACONs for venlafaxine-
XR and pregabalin were 1.61 and 2.49, respectively. Duloxetine and pregabalin had 
similar average daily costs among patients with DPNP or FM, while the numbers were 
signiﬁcantly lower for duloxetine than venlafaxine-XR among patients with MDD or 
GAD. Results for 2006 were similar. CONCLUSIONS: Duloxetine has stable DACON 
across disease states and over time. Average daily costs were similar for duloxetine 
and pregabalin, but better for duloxetine versus venlafaxine-XR. 1First DataBank’s 
National Drug Data File™ accessed via Analysource Online, June, 2009.
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OBJECTIVES: The academic area of the Tertiary Education constitutes an important 
ﬁeld of adjustment and transaction of the young in the post adolescence age with 
particular tensions, pressures and stress. The objectives of this study are to focus on 
the extent of drug use in this student community and the investigation of the relation-
ship between socioeconomic factors, toxic habits and drug use. METHODS: The 
sampling was selected out of a population of 27,930 students according to stratiﬁed 
sampling weighed by gender, department and semester. The sample size was 829 stu-
dents, that is sufﬁcient for the estimation of the proportion of users with a signiﬁcance 
level of 0.05. The questionnaire comprised 83 items concerning sociodemographic and 
economic characteristics, adjustment to the academic environment and use of sub-
stances. RESULTS: A total of 161 persons, (19.4%) have used drugs at least once. 
There are signiﬁcant differences (p  0.01) between users and non users concerning: 
gender, relations between parents, satisfaction on study, alcohol use, smoking, number 
of cigarettes/day, friends that are drug users, age of smoke beginners, spending the 
night. Discriminant analysis has indicated that the discriminant factors between depen-
dents/on a crucial phase, before dependence and non users are: friends that are drug 
users (0.707), alcohol use (0.627), age of smoke beginners (0.608), relationship 
between parents (0.392). CONCLUSIONS: It is evident the resulting relationship 
between illegal and legal psychotropic substances. Consequently, prevention policy 
should not ignore tobacco and alcohol use. Additionally it is evident the predominant 
role of the social environment in the use of substances.
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OBJECTIVES: Benzodiazepines (BZDs) as anxiolytics, sedatives and hypnotics are 
frequently prescribed in daily medical practice worldwide and their abuse also becomes 
a target of public health measures. Because frequent attenders to emergence depart-
ments (EDs) sometimes display different psychological features, the utilization pattern 
of BZDs among this group of patients deserves investigations. METHODS: The data 
sources came from the historical claims datasets of 1,000,000-person cohort 
(LHID2005) in 2007, offered by the National Health Insurance Research Database in 
Taiwan. BZDs were deﬁned as those drug items belonging to groups of N03AE, 
N05BA, N05CD and N05CF in the ATC (Anatomical Therapeutic Chemical) classi-
ﬁcation system. For each beneﬁciary, the annual numbers of visits to EDs of hospitals 
and ambulatory visits to practicing clinics and outpatient departments of hospitals 
(excluding visits to dentistry and traditional Chinese medicine) with BZDs prescrip-
tions in 2007 were calculated. RESULTS: Among the valid 962,768 beneﬁciaries of 
the 1,000,000-person cohort, 157,865 (16.4%) patients (96,004 females and 61,861 
males; mean age 52.0 o 17.8 [SD] years) had received BZDs during ambulatory visits 
and 156,259 (16.2%) patients (76,644 females and 79,615 males; mean age 38.5 o 
23.5 [SD] years) had visited EDs in 2007. Among the 806,509 beneﬁciaries who did 
not visit EDs in 2007, only 14.5% (n  116,554) had ever received BZDs at ambula-
tory visits during the year. In contrast, 26.4% (n  41,311) of the ED attenders had 
received BZDs: the percentage rose from 22.6% in one-time ED attenders to 78.8% 
in those having more than 12 ED visits in a year. CONCLUSIONS: The use of BZDs 
was strongly associated with ED visits in Taiwan. Further stratiﬁed analyses are 
required to elucidate this phenomenon.
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OBJECTIVES: Medicine abuse is deﬁned as the recurrent use of a medicine in a non-
medical manner for non-medicinal purposes. The potential for abuse of combination 
(polycomponent) analgesics is high. The primary aim was to detect the potential abuse 
of combination analgesics using a medicine claims database. METHODS: An analysis 
of the South African combination analgesic market was made. Thereafter, a retrospec-
tive, exposure-cohort drug utilisation study was conducted on a medicine claims 
database of a medical aid administrator. The medicine ﬁle contained 1,357,717 
records for 2007. RESULTS: From the analysis of the combination analgesics avail-
able, it was found that there were 21 Schedule 5 (prescription-only) tablet formula-
tions (trade names) containing the following identical active ingredients: 320 mg 
paracetamol, 8 mg codeine phosphate, 32 mg caffeine and 50 mg meprobamate. From 
the database study, a total of 145,372 analgesics were prescribed (36.82% were avail-
able without a prescription). Combination analgesics accounted for 30.21% of all 
analgesics prescribed (92,181 products at a cost of R2,784,484). Analgesics were often 
prescribed on an acute basis in excessive quantities, for example 200 tablets. Combina-
tion analgesic tablets and capsules were also often dispensed to children in large 
quantities. For example, 10 prescriptions for 100 tablets of an over-the-counter com-
bination analgesic and eight prescriptions for 100 capsules of a prescription-only 
combination analgesic, were dispensed to children under seven years, while a syrup 
(a more suitable dosage form) was available. There was furthermore concern about 
the quantities of analgesics prescribed to speciﬁc families and it was clear that if the 
medical aid beneﬁt of one family member was exhausted, the analgesic was claimed 
under another family member’s name. A number of prescribers were identiﬁed who 
were over-prescribing speciﬁc analgesics. CONCLUSIONS: A medical aid database 
can be used to detect analgesic abuse and guidelines to control abuse and cost were 
proposed.
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OBJECTIVES: Although health spending is well below the OECD average when con-
sidered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of 
total health care budget. The accessibility and availability of innovative drugs is good. 
Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH 
set the ofﬁcial threshold by l1  a18,000/QALY and l2  a26,500/QALY. METHODS: 
We have analysed the legislation and ofﬁcial reimbursement decisions and commentar-
ies, published by the MoH in 2009. We analysed the applicants documentation 
including pharmacoeconomic analysis, as a mandatory part of the application. 
RESULTS: The main drug reimbursement body—Categorisation committee of the 
MoH—and pharmacoeconomic advisory committee evaluated the applicants dossier 
for the drug agomelatine (Valdoxan®, Servier Slovakia) for the treatment of depres-
sion. The pharmacoeconomic part of the application fulﬁled all legislative aspects. The 
CUA analysis was taken from Swedish pharmacoeconomic model and extrapolated in 
Slovak environment. CMA in Slovak conditions shows lower drug costs for agomela-
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tine as for comparator. The price sensitivity analysis of comparators was done. The 
reassessment of CEA after price cut of comparators (up to—10%, due to international 
price referencing) has showed the positive results for agomelatine and robustness of 
previous price sensitivity analysis. CONCLUSIONS: The focus of the MoH drug 
policy is on more rational spendings , especially on reference pricing and HTA. There 
are ﬁrst results of these new procedures, where the real impact of the HTA in the 
decision processes is demonstrated. Agomelatin, a new agent in therapy of depression 
fulﬁlled, the necessary legislative conditions including pharmacoeconomic aspects to 
be listed in the positive reimbursement list.
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OBJECTIVES: To examine whether non-generic duloxetine and venlafaxine XR are 
essentially interchangeable in patients with major depressive disorder (MDD) or used 
selectively for patients with different treatment histories, costs, demographics, and 
comorbidities. METHODS: Using the US PharMetrics Database, we studied com-
mercially insured individuals aged 18–64 initiating treatment with duloxetine or ven-
lafaxine XR between July 2005 and July 2006, with q1 prior MDD diagnosis and 
continuous enrollment for 12 months prior to initiation date. Initiation was deﬁned 
as the ﬁrst use of either medication preceded by 3 months no prescription for or use 
of the same medication. Chi-square and logistic regression analysis of patients’ demo-
graphics, past-year medication use, and comorbidities were used to assess predictors 
of initiations with duloxetine versus venlafaxine XR. RESULTS: A total of 9641 
patients (73.6% female) initiated treatment with duloxetine and 8514 (71.5% female) 
with venlafaxine XR. Compared to venlafaxine XR patients, duloxetine patients were 
older (45 vs. 42.4 years), had q3 unique prior pain medications (25.5% vs. 15.6%), 
SSRIs (59.5% vs. 52.7%), TCAs (12.6% vs. 7.8%), analgesics (63.1% vs. 51.3%), 
anticonvulsants (30.1% vs. 17.9%), hypnotics (30.2% vs. 22.3%), and had q8 unique 
comorbid medical conditions (38.6% vs. 29.1%) and pain diagnoses (76.3% vs. 
67.8%) (all p-values 0.005). Logistic regression results revealed that 61% of dulox-
etine initiators and 61% of venlafaxine XR initiators were predictable from prior 
patient and treatment factors. The prior 6-month total health care costs were $1731 
higher for future duloxetine patients than for future venlafaxine XR patients, and 
despite higher subsequent pharmacy costs, total health care costs declined for both 
medications after treatment with each drug began. CONCLUSIONS: MDD patients 
treated with duloxetine tended to have a more complex and costly antecedent clinical 
presentation compared with venlafaxine XR-treated patients, suggesting physicians do 
not use the two medications interchangeably and both may have unique roles on 
formularies.
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OBJECTIVES: This retrospective study aimed to explore predictors of duloxetine 
versus other antidepressants for treating patients with major depressive disorder 
(MDD) in the Veterans Affairs (VA) health system. Duloxetine was not on the VA 
national drug formulary. METHODS: The electronic medical records from October 
2004 to October 2008 were extracted from the VA Veterans Integrated Service 
Network 16 data warehouse. All patients were treated with either duloxetine mono-
therapy (duloxetine) or other antidepressants (non-duloxetine) over the study period, 
with the ﬁrst dispense date of the index agent as the index date. All patients must 
have at least 1 prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3), but no prior dia-
betes (ICD-9-CM: 250.xx) or bipolar disorder (ICD-9-CM: 296.4x-296.8x) diagnosis. 
Logistic regression was used to examine the predictors of treatment of duloxetine 
versus other antidepressants, controlling for demographics, comorbidities, prior 
opioid use, and pain level in the 12 months pre-index period. RESULTS: The logistic 
regression sample included 12,077 patients (duloxetine: n  448; non-duloxetine: n  
11,629). Patients who were female (odds ratio [OR]  3.15, 95% Conﬁdence Interval 
[CI]: 2.48–4.00), white (OR  1.48, CI: 1.15–1.91), with non-VA insurance (OR  
1.69, CI: 1.24–2.31), or prior emergency department (ED) visit (OR  1.64, CI: 
1.21–2.22) were more likely to use duloxetine. Patients comorbid with dyslipidemia, 
hypertension, or substance abuse were 1.60 (CI: 2.08–3.25), 0.35 (CI: 1.09–1.68), and 
0.41 (CI: 1.14–1.75) times more likely to use duloxetine. Prior short-acting and long-
acting opioid users were 3.32 (CI: 2.60–4.23) and 8.98 (CI: 6.95–11.60) times as likely 
to use duloxetine as those with no prior opioid use, respectively. Patients with self-
reported moderate or severe pain were 1.43 (CI: 1.07–1.90) or 1.50 (CI: 1.16–1.92) 
times as likely to use duloxetine as those with no pain. CONCLUSIONS: The VA 
patients who were treated with duloxetine appeared to have more ED visits, more 
comorbid conditions, prior substance abuse or opioid use, and higher pain levels.
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OBJECTIVES: To determine if patients are adherent with interferons used to treat 
patients with Multiple Sclerosis (MS), the optimal adherence rate to maximize clinical 
outcomes, and the impact of adherence on the number and severity of relapses. 
METHODS: A retrospective cohort study design was used. Pharmacy and medical 
claims data were extracted for 2006–2008. Adherence was measured using two stan-
dard methods for Medication Possession Ratio (MPR), one that incorporates persis-
tence and one that does not. Threshold analyses were run to determine an optimal 
adherence rate to minimize relapses. Patients were considered adherent if they met a 
predeﬁned standard cut-off point and reanalyzed with the newly determined cut point. 
The number and severity of relapses were measured for each patient year, with 2008 
being the critical outcomes point. A series of regression models were used to assess 
the impact of adherence on the number and severity of relapses. RESULTS: A total 
of 3590 patients were included in the study. Based on the method, the average MPR 
varied between 77.6% and 89.8%. The threshold analysis determined that the optimal 
adherence rate is around 85%. Patients receiving interferon through a specialty phar-
macy are more adherent than those who did not. Patients who were classiﬁed as 
adherent through 2007 had a signiﬁcantly lower risk of relapse in 2008. Patients who 
were adherent also had a signiﬁcantly lower risk of severe relapse than those who 
were non-adherent. Complete MPRs, adherence rates, individual year descriptives, and 
inferential statistics will be included in the presentation. CONCLUSIONS: Patients 
with MS are generally adherent with their interferon therapy, although opportunities 
for improvement exist. Patients who receive special pharmacy services are more adher-
ent than those who receive standard retail services. The effect of adherence on the 
number and severity of relapses demonstrated the positive impact of interferons for 
MS treatment.
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OBJECTIVES: The aim of this study was to evaluate the efﬁcacy for ﬁve FDA 
approved drugs for Alzheimer’s disease. METHODS: MEDLINE and the International 
Pharmaceutical Abstracts databases were searched for studies addressing functional 
outcomes with Alzheimer’s disease. The primary outcome was cognitive efﬁcacy and 
must have been measured on a validated scale. To report one consistent scale value, 
values were transformed into z-scores to obtain a dichotomized output, categorized 
as either improvement or a lack therof in treatment. Odds ratios were calculated for 
success for each drug treatment. Winbugs version 1.4 statistical software was used to 
conduct a mixed treatment comparisons Bayesian analysis along with a sub-analysis 
to examine whether or not the cognitive measurement scale used in the studies effects 
the ranking of drug treatments. RESULTS: The mixed treatment comparisons results 
showed that galantamine OR  2.518E7, 95%CRI: 447,300–7.034E9 was highly 
favored above all other Alzheimer’s treatments, followed by donepezil OR  1557, 
95%CRI: 315.4–8341, tacrine OR  212.8, 95%CRI: 28.47–1604, rivastigmine OR 
 23.57, 95%CRI: 5.397–104.8, memantine OR  3.775, 95%CRI: 0.639–23.09 
compared to placebo. The sub-analysis also showed that galantamine OR  2.832E7, 
95%CRI: 483900–2.326E10 as highly favored, but yielded slightly different results 
with tacrine OR  1434, 95%CRI: 148.2–15830 ahead of donepezil OR  471.2, 
95%CRI: 83.48–2935 in ranking, followed by rivastigmine OR  19.54, 95%CRI: 
4.781–83.19 and memantine OR  2.836, 95%CRI: 0.2196–37.96. This analysis 
removed the eight studies that did not use the ADAS-Cog measurement scale, suggest-
ing that the selection of the cognitive measurement scale changes the ranking of drug 
treatments. Odds ratios for galantamine were high due to the favorable response (q95) 
for the drug. The severity of Alzheimer’s disease was not taken into account in this 
study. CONCLUSIONS: The consistency between drugs in terms of cognitive efﬁcacy 
is present in all ﬁve drugs; all demonstrating effectiveness over placebo. Future 
research in this area is needed, including clinical studies comparing the agents 
directly.
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OBJECTIVES: The aim of this meta-analysis was to evaluate the efﬁcacy and tolerabil-
ity of Natalizumab in relapsing multiple sclerosis (MS). METHODS: “Mean change 
in Expanded Disability Status Scale (EDDS)”, “number of patients with at least one 
relapse”, and “number of patients with at least one new gadolinium (Gd)-enhancing 
lesion” were the key outcomes of interest for assessment of efﬁcacy. “Any adverse 
events”, “serious adverse events”, “death”, and “withdrawal because of adverse 
events” were the key outcomes for tolerability. RESULTS: Amongst existing trials, 
four randomized placebo controlled clinical trials met our criteria and were included. 
